Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan
Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells
Cerus Corporation (NASDAQ:CERS) today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35th Regional International Society of Blood Transfusion (ISBT) Congress being held May 31 to June 4, 2025, in Milan.
"The breadth of data being presented this year underscores the broad applicability of the INTERCEPT system for platelets, plasma, and cryoprecipitated fibrinogen complex as well as the potential benefit for red blood cells," said Richard J. Benjamin, Cerus' chief medical officer. "Importantly, we are looking forward to sharing the positive results from our Phase 3 ReCePI study in red blood cells, INTERCEPT treated cold stored platelets, and effective inactivation of California encephalitis virus with the blood transfusion community."
The following is a list of selected presentations and abstracts of interest for Cerus. All presentation times are listed in Central European Summer Time (CEST). The full program of Cerus-related abstracts can be found at the following link: https://intercept-usa.com/wp-content/uploads/2025/05/2025_ISBT_AbstractBook_v2final.pdf.
Cerus Sponsored Symposium
Sunday, June 1, 2025 – 12:45 – 13:45 - INTERCEPT™ - Much more than just Pathogen Inactivation
- Use of INTERCEPT platelet concentrates in France: impact on adverse events, platelet use and inventory management
- INTERCEPT platelets: Impact on the occurrence of pulmonary adverse events in haematology-oncology patients
- Safety and Efficacy of INTERCEPT treated platelets transfused to mature and premature neonates
Oral Presentations
Monday, June 2, 2025 – 09:45 – 10:00 - Cold-stored amotosalen-UVA pathogen-reduced platelet concentrates display distinct platelet subpopulations with specific functional properties
Monday, June 2, 2025 – 14:15 – 14:30 - Reduced hemoglobin use with amustaline/glutathione pathogen-reduced red cells in complex cardiac surgery: results of a randomized, controlled Phase III trial
Monday, June 2, 2025 – 16:15 – 16:30 - Surface-bound acridine as a novel marker to track entire units of transfused pathogen-reduced red cells in sickle cell patients
Selected Poster Presentations
Monday, June 2, 2025 – 17:15 – 18:15
- P220: Evaluation of Whole Blood Plasma Pool Stability After Treatment for Pathogen Reduction With Amotosalen/A Prototype LED Illuminator and 2 Years of Storage
- P276: In Vitro Evaluation of Cold Stored and Room Temperature Double Dose Platelets Treated With Amotosalen and UVA Light
- P279: Hemostatic Functions of Platelets and Their Subpopulations According to Platelet Concentrate Storage Conditions, Assessed by Viscoelastic Platform
- P287: Pathogen Reduced Cryoprecipitated Fibrinogen Complex Supports Collagen-Mediated Platelet Adhesion and Thrombus Formation of Pathogen-Reduced Platelet Components Stored Up to Seven Days
- P307: Inactivation of California Encephalitis Virus in Platelet Concentrates Using Amotosalen and UVA Treatment
- P472: Investigations into the Clinical Significance of Treatment-Emergent Antibodies to Amustaline/Glutathione Pathogen-Reduced Red Blood Cells
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250529887759/en/
Tim Lee – Head of Investor Relations
Cerus Corporation
925-288-6128